The cobas® BKV test provides reliable, standardized, high-quality results for the improved management of transplant patients at risk of infection. Healthcare professionals use this test in conjunction with with clinical signs and symptoms and relevant laboratory findings to assess if transplant patients are at risk of developing disease caused by BKV, which can contribute to graft loss or organ rejection. The test is for use on the automated cobas® 5800/6800/8800 Systems.
Features and benefits of the cobas® BKV test
- Standardization - Results traceable to the WHO International Standard and reporting in IU/mL for improved harmonization in testing results across hospitals and institutions
- State-of-the-art design - Best-in-class design with a dual target assay design to provide reliable and reproducible results for reassurance in clinical decision making
- Efficiency, flexibility and simplicity - Ability to perform critical transplant testing (CMV, EBV, BKV) from a single sample on the cobas® 5800/6800/8800 Systems with an industry-leading menu, absolute automation and proven performance
- Enabling BKV urine testing the right way - Urine sample stabilized in cobas® PCR media allows result integrity to be maintained, enabling faster preparation and making storage and transportation more convenient without the need of refrigeration
BKV could cause transplant-transmitted infections in immunocompromised transplant patients and is linked to post-transplant complications, such as nephropathy in kidney transplants and hemorrhagic cystitis in hematopoietic stem cell transplants.1,2 Early intervention with best-in-class monitoring tools provides actionable results which enable informed treatment decisions.